IP Library Granted Patent US 9,732,128
Granted Patent B2
US 9,732,128 · App. 13/279,123 · Granted Aug 15, 2017

Methods of modifying transcriptional regulatory networks in stem cells

Inventors: Michael D. West (Mill Valley, CA); Karen B. Chapman (Mill Valley, CA)
Assignee: BioTime, Inc.
C07K14/4702C12N5/0696C12N2501/602C12N2501/603
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 9,732,128
App. No.
13/279,123
Granted
Aug 15, 2017
Kind
B2
Abstract

The vast differentiation potential of human embryonic and induced pluripotent stem cells, including their potential to cascade through all of the somatic cell lineages and to display the complete transcriptional regulatory network of human biology, has generated interest in deriving scalable, purified, and identified cell types and methods of discovering the precise structure of the human regulatory network. However, the innate capacity of pluripotent cells to display all these lineages is not necessarily reflected during their culture in vitro. The clonal isolation and propagation of progenitors greatly facilitates the generation of highly purified and identified formulations for research and therapeutic purposes. Nevertheless, other cell types have yet to be isolated and propagated from normal cells and methods of isolating said novel cell types as well as methods for introducing perturbations into the transcriptional regulatory network in order to construct a computer model of the entire human transcriptional regulatory network would greatly benefit basic research as well as manufacturing technology for cell-based therapies.

Claims (5)

1. An isolated progenitor cell line, wherein said isolated progenitor cell line constitutively expresses OCT4 and a transcription factor selected from the group consisting of SIX1, FOXA1, SOX17, SIX2, SOX21, PAX6, MYOD1, MYOG, NEUROG1, NKX2.5, and combinations thereof, wherein the expression level of OCT4 is greater than the expression level of OCT4 in an iPS cell.

2. The isolated progenitor cell line of claim 1 , wherein said progenitor cell line expresses LHX3.

3. An isolated progenitor cell line, wherein said progenitor cell line expresses the genes RESP18 and LHX3 simultaneously and is the in vitro progeny of a pluripotent stem cell.

4. An isolated progenitor cell line, wherein said isolated progenitor cell line constitutively expresses a transcription factor and is a differentiated cell line differentiated in vitro from a pluripotent stem cell.

5. The isolated progenitor cell line of claim 3 , wherein the cell line expresses the gene ESR2.

Assignments (2)
CHANGE OF NAME Recorded Jul 14, 2020
From: BIOTIME INC
To: LINEAGE CELL THERAPEUTICS, INC.
Reel/Frame 053197/0627 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Feb 28, 2012
From: WEST, MICHAEL D.; CHAPMAN, KAREN B.
To: BIOTIME, INC.
Reel/Frame 027778/0195 →
Continuity (3)
Provisional Application 61415244 · Nov 18, 2010
Provisional Application 61406064 · Oct 22, 2010
Related Publication 20120129262A1 · May 24, 2012